Wuhan Institute of Virology, Chinese Academy of Sciences, WuChang District, Wuhan 430071, China.
Vaccine. 2012 Aug 3;30(36):5316-23. doi: 10.1016/j.vaccine.2012.06.053. Epub 2012 Jun 27.
The greatest challenge of HIV vaccine development lies in the diversity of circulating HIV-1 strains. For an effective vaccine, neutralizing antibodies are assumed to be of crucial importance, but previous attempts results only very limited breadth and potency of Nab titer. While the amino acid sequences of lentivirus envelope have many differences, those envelope proteins share almost same structural conformations. If the envelopes of different lentivirus were used immune animals, the response to the conserved sites will be strengthened while the un-conserved sites will not be. In this study, compared to only protein immunization regimen, HIV-1 CN54 gp140 DNA prime and protein boost strategy generated Nab titer increased significantly. So, the prime-boost strategy and HIV-1 CN54 gp140 protein were employed to different lentivirus cross immunization schedule. The results indicated that, the different lentivirus and HIV-1 cross immune by prime-boost strategy elicited breath and potency neutralization antibody to tier 1, tier 2, and tier 3 viruses with 14 tested viruses. To tested tier 2 and tier 3 viruses, in SIV and HIV-1 cross immunization group, the neutralization breadth of ID50 is 91.7% and the breadth of ID70 is 50%; in HIV-1, FIV and SIV cross immunization group, the breadth of ID50 is 83.3% and the breadth of ID70 is 58.3%, while in only HIV-1 vaccinated group, the breadth of ID50 is 75% and the breadth of ID70 is only 25%. These data demonstrate that HIV-1 and different lentivirus especially with SIV cross immunization by prime-boost strategy elicit broad neutralizing antibodies much better than only HIV-1 immunization.
HIV 疫苗开发面临的最大挑战在于循环 HIV-1 毒株的多样性。对于有效的疫苗,中和抗体被认为是至关重要的,但之前的尝试结果仅显示出纳布滴度非常有限的广度和效力。虽然慢病毒包膜的氨基酸序列有很多差异,但这些包膜蛋白具有几乎相同的结构构象。如果使用不同的慢病毒包膜来免疫动物,对保守位点的反应将会增强,而对非保守位点的反应则不会。在这项研究中,与仅进行蛋白免疫的方案相比,HIV-1 CN54 gp140 DNA 初免和蛋白加强策略产生的纳布滴度显著增加。因此,采用 HIV-1 CN54 gp140 蛋白的初免-加强策略对不同的慢病毒进行交叉免疫。结果表明,通过初免-加强策略对不同的慢病毒和 HIV-1 进行交叉免疫,可以诱导产生针对 1 型、2 型和 3 型病毒的广泛而有效的中和抗体,用 14 种测试病毒进行了测试。在 SIV 和 HIV-1 交叉免疫组中,对测试的 2 型和 3 型病毒,ID50 的中和广度为 91.7%,ID70 的广度为 50%;在 HIV-1、FIV 和 SIV 交叉免疫组中,ID50 的广度为 83.3%,ID70 的广度为 58.3%,而在仅接受 HIV-1 免疫的组中,ID50 的广度为 75%,ID70 的广度仅为 25%。这些数据表明,HIV-1 和不同的慢病毒,特别是通过初免-加强策略进行的 SIV 交叉免疫,比仅进行 HIV-1 免疫能更好地诱导广泛的中和抗体。